Navigation Links
First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System
Date:3/17/2008

WILMINGTON, Mass., March 17 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has enrolled its first patient in the SONIC I Clinical Registry. SONIC I is a prospective, multi-centered U.S. registry study of the company's OmniWave(TM) Endovascular System (OES) in patients undergoing percutaneous mechanical thrombectomy of acute deep vein thrombosis (DVT). All patients enrolled in the SONIC I are scheduled for follow-up at 30 days and 6 months following the OmniWave procedure. The first patient was enrolled by Daniel Clair, M.D., Chairman of Vascular Surgery at The Cleveland Clinic.

"The Cleveland Clinic is excited to participate in the SONIC I clinical trial with the OmniWave Endovascular System," said Dr. Clair. "The OmniWave System has the potential to offer physicians an effective alternative to current pharmacological and mechanical treatments for deep vein thrombosis (DVT)."

In response to this important milestone, Richard Ganz, President and CEO of OmniSonics Medical Technologies, said, "We continue to be encouraged by the positive outcomes the first physicians are having with the OmniWave Endovascular System. Enrolling our first patient in the SONIC I Clinical Registry is a key step in our contribution to providing tools to physicians for the treatment of DVT."

In September 2007, OmniSonics received clearance from the Food and Drug Administration (FDA) to market its catheter-based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature.

OmniSonics Medical Technologies, Inc. is scheduled to exhibit the OmniWave Endovascular System at the Society for Interventional Radiology (SIR) Meeting to be held March 15-20 in Washington, DC.

The OmniWave Endovascular System is based on patented OmniWave technology
'/>"/>

SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
6. First-Ever Cancer and Careers Seminar Debuts in Orange County
7. Pharmaxis First Steps into China
8. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
9. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
10. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
11. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3
... , MALVERN, Pa. and WALTHAM, Mass., Nov. ... find that the leading driver of antibiotic selection in ... and gram-negative pathogens. Due to the variety of organisms ... that they look primarily for agents that provide appropriate ...
... , MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a targeted ... , The study, entitled "An Open-Label Randomized Phase 2 ... AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin ...
... ... Consortium (IGSC) to Coordinate Best Practices in Risk Reduction ,Five Member Companies Represent ... ... leading gene synthesis companies today announced agreement that they will apply a common screening ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... reprogrammed stem cells from a key organ in the immune ... regeneration. Their research shows that it is possible to ... genetic modification. Researchers, who used rat models, grew ... our immune systems in the laboratory using conditions for ...
... destroys brain cells and their connections (called synapses), causing ... hobbies and daily life. Symptoms can be alleviated, in ... States as Namenda), which is currently FDA-approved to treat ... Stuart A. Lipton, M.D., Ph.D., Director of the Del ...
... Tech College of Engineering researchers have received a $60,000 ... occurring microbes can best be used to eat away ... Their choice of weapon: Geometry. Fueled by oxygen, ... of crude oil without the use of additional chemicals. ...
Cached Biology News:Stem cell versatility could help tissue regeneration 2Study explains why Alzheimer's drug is both safe and effective 2Does the shape of crude oil remnants impact rate of biodegradation? 2Does the shape of crude oil remnants impact rate of biodegradation? 3
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... functionally defined by their capacity to self ... multiple specialized progenitor cells, which can commit ... stem cells (NSCs) are capable of differentiating ... and oligodendrocytes. During the isolation and expansion ...
Lineage cocktail 1 (lin 1) 50 tests...
Biology Products: